Macrophage inflammatory protein 3 beta (MIP-3 beta)

Macrophage inflammatory protein 3 beta (MIP-3 beta; CCL19, MIP-3ß) is constitutively expressed in various lymphoid tissues (including thymus, lymph nodes, appendix and spleen). Its expression is downregulated by IL10. MIP-3 beta may play a role in normal lymphocyte recirculation and homing, as well as regulating the encounters between DC and T cells

Swiss-Prot Accession Number: Q99731


Publications
Phase Ib Study of Glasdegib, A Hedgehog Pathway Inhibitor, in (2018) Savona M, Pollyea D, Stock W, Oehler V, Schroeder MA, Lancet J, McCloskey J, Kantarigian H, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE Clinical Cancer Research
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment (2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One
Circulating Biomarkers and Outcome from a Randomised Phase Ii Trial of Sunitinib Vs Everolimus for Patients with Metastatic Renal Cell Carcinoma (2016) Voss MH, Chen D, Marker M, Hakimi AA, Lee C-H, Hsieh JJ, Knox JJ, Voi M, Motzer RJ British Journal of Cancer
Variation in Serum Biomarkers with Sex and Female Hormonal Status: Implications for Clinical Tests (2016) Ramsey JM, Cooper JD, Penninx BWJH, Bahn S Scientific Reports
Phase I Trial of the Pan-Pi3k Inhibitor Pilaralisib (Sar245408/Xl147) in Patients with Chronic Lymphocytic Leukemia (Cll) or Relapsed/Refractory Lymphoma (2015) Brown JR, Davids MS, Rodon J, Abrisqueta P, Kasar SN, Lager J, Jiang J, Egile C, Awan FT American Association for Cancer Research